Adolor Corporation (ADLR) and GlaxoSmithKline (GSK) Announce Pertinent Extension
Adolor Corporation (ADLR) and GlaxoSmithKline (GSK) announced that the U.S. Food and Drug Administration has informed Adolor that the Prescription Drug User Fee Act action date for Adolor's ENTEREG product has been extended to May 10, 2008. Additionally, Adolor has also submitted an elaborate ENTEREG Risk Management Program to the FDA. ENTEREG 12 mg capsules were designed specifically for in hospital, short term use. Adolor asserts that this drug is able to accelerate upper and lower gastrointestinal recovery following partial large or small bowel resection surgery. Currently, there are no other FDA approved drugs for this indication. Michael R. Dougherty,…